



Important Information Regarding Tirosint® and Medicaid Coverage: Action Required for Pharmacy Providers and Prescribers

Please be advised of an important change affecting Medicaid coverage for Tirosint® (levothyroxine sodium), manufactured by IBSA Pharma, and its generic equivalent by YARL Pharma INC.

Effective October 1, 2024, IBSA Pharma and YARL Pharma INC will no longer participate in the Medicaid Drug Rebate Program.

Impact on Patients:

Prior Authorization: Please note that prior authorization will not be available for this medication for Medicaid patients after October 1, 2024.

Recommended Action: Prescribers should transition patients currently on Tirosint® or its generic equivalent to an alternative levothyroxine product covered under the Medicaid program.

Resources:

For a complete list of preferred drug alternatives, please visit the DMMA 2025 Medicaid Preferred Drug List: [DMMA 2025 Preferred Drug List](#)

For questions or concerns, please contact Highmark Health Options at 1-844-325-6251.

We understand this change may require adjustments to your prescribing practices and appreciate your cooperation in ensuring continuity of care for our members.